Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Increase in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 12,800 shares, an increase of 16.4% from the November 30th total of 11,000 shares. Based on an average daily trading volume, of 27,000 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the company are short sold.

Aprea Therapeutics Stock Performance

Shares of APRE opened at $3.48 on Tuesday. Aprea Therapeutics has a one year low of $2.15 and a one year high of $8.85. The stock’s fifty day moving average is $3.43 and its 200-day moving average is $3.49. The firm has a market capitalization of $18.91 million, a price-to-earnings ratio of -1.24 and a beta of 0.88.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. Analysts forecast that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Insider Activity at Aprea Therapeutics

In related news, Director Marc Duey sold 6,462 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.58, for a total transaction of $29,595.96. Following the completion of the transaction, the director now directly owns 233,651 shares in the company, valued at $1,070,121.58. This represents a 2.69 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bernd R. Seizinger bought 10,000 shares of the business’s stock in a transaction on Friday, October 11th. The stock was bought at an average price of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the purchase, the director now directly owns 44,730 shares of the company’s stock, valued at $119,876.40. The trade was a 28.79 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 42,290 shares of company stock valued at $165,096 in the last quarter. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 34.19% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Tuesday, December 17th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.